BioArdis is an innovative therapeutic development company with a pipeline of oncology and immuno-oncology drug candidates, and a novel chimeric antigen receptor T cell (“CAR-T”) platform with multiple therapies targeting solid tumors.
BioArdis was founded with the vision of discovering and developing best-in-class small molecule therapies in emergent oncology and immune-oncology indications. BioArdis’s oncology pipeline now includes four pre-clinical oncology programs. In addition, BioArdis has developed a novel, first-in-class dermatological therapy that is in advanced lead optimization.
BioArdis launched its cell therapy platform with a mission to develop first-in-class CAR-T therapies that target solid tumors with a high degree of precision, safety and efficacy. BioArdis is powered by a proprietary, accelerated high-throughput screening engine that has allowed the company to develop multiple therapies, with two candidates currently undergoing IND-enabling studies.
Kedar Muley is a seasoned executive with nearly 20 years of biopharma, investment banking and strategic advisory experience. He spent eleven years with J.P. Morgan where he advised companies on corporate strategy, portfolio assessment and partnering, financing alternatives and mergers and acquisitions. Kedar executed nearly twenty biopharma transactions totaling over $200 billion in value throughout his tenure. Prior to J.P. Morgan, Kedar was a consultant with Watson Wyatt Worldwide where he advised companies on their executive compensation practices. Most recently, Kedar was an independent advisor to biotechnology companies on corporate development, strategy and financial planning.
Kedar holds an MBA from The Wharton School of the University of Pennsylvania and a B.A. in Physics from The University of Chicago.
Farzad Haerizadeh oversees and manages large molecule and cell therapy pipelines and programs at BioArdis.
Farzad has more than 20 years of experience in the life sciences and biotech industries with a strong focus on adaptive cellular and immuno-oncology products including CAR-T, allogeneic CAR-T, allogeneic ‘off the shelf’ stem cell/iPSC products, mammalian genome editing and synthetic biology. In the past several years he served as the VP of preclinical IO platform development in F1Oncology/ Exuma Inc.
He also held multiple key R&D roles in several pharma/biotech companies such as Intrexon, Synthetic Genomics, Life Technologies Corporation (Thermifisher Scientific) and Codexis Inc. where he initiated and directed multiple cutting-edge adaptive cell therapy (engineering T cells, T cell receptors (TCRs), NK cells) and therapeutics discovery platforms, xenotransplantation, protein engineering and industrial enzymes evolution programs. He is also experienced in bio-manufacturing and product development.
Farzad holds a PhD and a postdoctoral fellowship in Molecular, Cellular & Systems Biology from the University of Melbourne, Australia, and a postdoctoral fellowship from Stanford University, California.
Frank Kayser spearheads all aspects of small molecule discovery at BioArdis. With expertise in medicinal chemistry and structure-based drug design, Frank has developed numerous candidates for neuroscience, cardiovascular disease, metabolic disorders, oncology, and immunology. He has led multidisciplinary teams that progressed compounds from early chemical leads into optimized clinical candidates, including multiple Ph2 and Ph1 clinical compounds.
Previously, Frank was Senior VP Chemistry for Integrated Programs at BioDuro. Additionally, he’s held research and management positions in the pharmaceutical industry at Merck, Tularik and Amgen.
Frank is a co-author on more than 40 peer-reviewed publications as well as an inventor of more than 40 US-issued and corresponding international patents, and multiple pending US and PCT applications. Frank has a Ph.D. in Chemistry at the University of Marburg, Germany with Prof. M. T. Reetz, and a Postdoctoral fellowship with Prof. B. H. Lipshutz at the University of California, Santa Barbara.
Helena (Liqun) Jiang brings over 17 years of industry R & D and management experience in drug discovery programs to BioArdis. Her vast experience includes target validation, assay development and validation, SAR funnel development, compound screening and MoA studies for various target families and disease areas. Helena is responsible for program management and supervising BioArdis operations in China.
She has managed hundreds of projects for pharmaceutical/biotech companies in the US, Europe and China resulting in value-added contributions to their pipelines while working for leading companies including Adlai Nortye, BioDuro and HD Biosciences.
Helena’s education includes a Master of Science in Cellular and Molecular in biology from Peking Union Medical College, graduate school work and Research Associate with University of Texas at Austin, and an Executive MBA from University of Plymouth.
Dr. Masood Tayebi is a Founding Partner and the CEO of the Bridgewest Group. He has a wealth of experience commercializing new technology, particularly in pharmaceutical and biotechnology sectors, as well as the wireless communications sectors. Dr Tayebi is directly responsible for managing Bridgewest investments in biotechnology and pharmaceuticals, hi-tech and wireless technologies, and software.
He has successfully founded many companies, including a global wireless communications service company, a disruptive semiconductor IP technology company, and a CRO company with over 1,000 employees with operations in the USA and China. Dr Tayebi has been integral in the success of multiple public and private companies alongside his brother, Dr. Massih Tayebi.
Cyrus K. Mirsaidi is the current chairman and managing partner of BioSelective Capital Investments, a Utah-based risk-capital biotech investment company with focus on early stage therapeutics and select translational opportunities. He is co-founder of BioArdis and a member of its Board of Directors.
In addition, Mr. Mirsaidi is an executive committee member and operating partner at Bridgewest Ventures, New Zealand, serves in Advisory roles with Advent International, and is on the Board of BioDuro-Sundia, a contract research, development and manufacturing company, where he served as President and CEO from 2015 to 2021. Prior to BioDuro-Sundia, Mr. Mirsaidi served as CEO of Formex, was the founder and CEO of Molecular Response, and served in key executive roles at AltheaDx, Ontogen, Inc. and Quest Diagnostics.
Mr. Mirsaidi received a BS in Biology from University of California, Irvine. Mr. Mirsaidi resides in Deer Valley, Utah, and relishes in sharing the wines he makes in his spare time with family and friends.
Ian Wisenberg has more than 35 years of experience in international business with an emphasis in finance, capital formation and business development. He is one of the founders and Chief Executive Officer of BioCina. He transitioned to this new role from Chief Financial Officer at BioDuro after its sale to Advent International in 2019. Ian is also a founder of BioArdis, a preclinical biopharmaceutical development company.
Previously, Ian ran a very successful consulting practice, BioGlobal Consulting Group, which had an extensive client list of biotech and pharma companies in the USA and abroad.
Ian is from Cape Town, South Africa, and attended the University of Cape Town.
BioArdis, an oncology focused therapeutics company with programs across its cell therapy and small molecule platforms, announces Kedar Muley as Chief Business Officer and acting Chief Executive Officer.
BEIJING China, SHANGHAI, China and SAN DIEGO USA, April 3, 2020 (PR NEWSWIRE) – Shenogen, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical
